Wedbush Issues Pessimistic Estimate for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report released on Wednesday, November 5th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn ($5.84) per share for the year, down from their previous estimate of ($5.58). Wedbush currently has a “Neutral” rating and a $34.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($1.30) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at $0.78 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. During the same period in the prior year, the firm earned ($1.40) EPS. The business’s revenue for the quarter was up 14.6% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS.

Several other research firms have also weighed in on RARE. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Truist Financial lowered their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday. Wells Fargo & Company assumed coverage on Ultragenyx Pharmaceutical in a report on Monday, October 20th. They issued an “overweight” rating and a $65.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Finally, TD Cowen dropped their target price on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $82.75.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $30.95 on Friday. Ultragenyx Pharmaceutical has a 1 year low of $25.81 and a 1 year high of $53.04. The firm’s 50-day moving average is $31.45 and its 200-day moving average is $32.89. The company has a market cap of $2.98 billion, a P/E ratio of -5.60 and a beta of 0.30.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the sale, the chief financial officer owned 98,227 shares of the company’s stock, valued at $3,095,132.77. The trade was a 7.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the transaction, the executive vice president directly owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 10,456 shares of company stock worth $328,486. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RARE. GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 323 shares during the period. Xponance Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company’s stock worth $455,000 after buying an additional 347 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of Ultragenyx Pharmaceutical by 5.1% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 340,975 shares of the biopharmaceutical company’s stock worth $12,347,000 after buying an additional 16,538 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Ultragenyx Pharmaceutical by 5.3% in the first quarter. New York State Common Retirement Fund now owns 61,667 shares of the biopharmaceutical company’s stock valued at $2,233,000 after buying an additional 3,096 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in Ultragenyx Pharmaceutical by 0.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 502,023 shares of the biopharmaceutical company’s stock valued at $18,178,000 after buying an additional 1,306 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.